866-997-4948(US-Canada Toll Free)

PharmaPoint: Non-Small Cell Lung Cancer - Spain Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jun 2013

Category :

Cancer

No. of Pages : 188 Pages


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

The NSCLC market in Spain is projected to decline at a negative CAGR. This contraction will be driven largely by the patent expirations of the majority of the marketed NSCLC therapies Alimta, Avastin, Iressa and Tarceva.

Scope

  • Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Spain from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Spain NSCLC market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Spain.
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14

3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology and Histology 15
3.1.3 NSCLC Biomarkers 16
3.1.4 Quality of Life 17
3.2 Symptoms 18

4 Disease Management 20
4.1 Treatment Overview 20
4.1.1 Diagnosis 22
4.1.2 Clinical Staging 23
4.1.3 Screening and Early Detection 25
4.1.4 Localized Procedures and Therapies 26
4.1.5 Systemic Chemotherapy 27
4.1.6 Targeted Therapy 27
4.2 Spain 30
4.2.1 Diagnosis 30
4.2.2 Clinical Practice 30

5 Competitive Assessment 32
5.1 Overview 32
5.2 Strategic Competitor Assessment 33
5.3 Product Profiles Major Brands, Chemotherapies 35
5.3.1 Alimta (pemetrexed disodium) 35
5.4 Product Profiles Major Brands, Targeted Therapies 40
5.4.1 Iressa (gefitinib) 40
5.4.2 Tarceva (erlotinib hydrochloride) 45
5.4.3 Xalkori (crizotinib) 50
5.4.4 Avastin (bevacizumab) 54

6 Opportunity and Unmet Need 58
6.1 Overview 58
6.2 Improved Overall Survival and Less Toxicity 59
6.3 Treatments for Patients with Acquired TKI Resistance 60
6.4 Better Treatment Options for Squamous Patients 61
6.5 Preventing Relapse or Recurrence 61
6.6 More Efficacious Second-Line Therapies 62
6.7 Increased Availability of Mutation Testing 62
6.8 More Cost-Effective Therapies 63
6.9 Unmet Needs Gap Analysis 64

7 Pipeline Assessment 68
7.1 Overview 68
7.2 Promising Drugs in Clinical Development 68
7.2.1 onartuzumab (MetMab) 72
7.2.2 necitumumab (IMC-11F8) 78
7.2.3 ramucirumab (IMC-1121B) 83
7.2.4 custirsen (OGX-011) 87
7.2.5 ganetespib (STA-9090) 92
7.2.6 nintedanib (BIBF1120) 98
7.2.7 Gilotrif (afatinib) 102
7.2.8 dacomitinib (PF-00299804) 108
7.2.9 LDK378 112
7.2.10 Yervoy (ipilimumab) 117
7.2.11 nivolumab (BMS936558) 121
7.2.12 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 127
7.2.13 Halaven (eribulin mesylate) 131

8 Market Outlook 136
8.1 Spain 136
8.1.1 Forecast 136
8.1.2 Key Events 139
8.1.3 Drivers and Barriers 140

9 Appendix 142
9.1 Bibliography 142
9.2 Abbreviations 160
9.3 Methodology 164
9.4 Forecasting Methodology 164
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 164
9.4.2 Percent Drug-treated Patients 165
9.4.3 Drugs Included in Each Therapeutic Class 165
9.4.4 Launch and Patent Expiry Dates 166
9.4.5 General Pricing Assumptions 167
9.4.6 Individual Drug Assumptions 170
9.4.7 Generic Erosion 179
9.4.8 Pricing of Pipeline Agents 179
9.5 Physicians and Specialists Included in This Study 182
9.6 Survey of Prescribing Physicians 183
9.7 About the Authors 184
9.7.1 Authors 184
9.7.2 Epidemiologists 185
9.7.3 Global Head of Healthcare 186
9.8 About GlobalData 187
9.9 Disclaimer 187

List of Table


Table 1: Symptoms of Disease NSCLC 19
Table 2: Treatment Guidelines for NSCLC 21
Table 3: Stage Definitions for NSCLC 24
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 29
Table 5: Leading Treatments for NSCLC 35
Table 6: Product Profile Alimta (pemetrexed disodium) 37
Table 7: Alimta SWOT Analysis, 2013 39
Table 8: Product Profile Iressa (gefitinib) 42
Table 9: Iressa SWOT Analysis, 2013 44
Table 10: Product Profile Tarceva (erlotinib hydrochloride) 46
Table 11: Tarceva SWOT Analysis, 2013 49
Table 12: Product Profile Xalkori (crizotinib) 51
Table 13: Xalkori SWOT Analysis, 2013 54
Table 14: Product Profile Avastin (bevacizumab) 55
Table 15: Avastin SWOT Analysis, 2013 57
Table 16: Overall Unmet Needs Current Level of Attainment 59
Table 17: Clinical Unmet Needs Gap Analysis, 2013 65
Table 18: Non-Small Cell Lung Cancer Phase I-II Pipeline, 2013 69
Table 19: NSCLC Phase III Pipeline, 2013 70
Table 20: NSCLC Advantages and Disadvantages of Therapeutic Classes 71
Table 21: Product Profile onartuzumab (MetMab) 73
Table 22: onartuzumab SWOT Analysis, 2013 78
Table 23: Product Profile necitumumab (IMC-11F8) 79
Table 24: necitumumab SWOT Analysis, 2013 82
Table 25: Product Profile ramucirumab (IMC-1121B) 83
Table 26: ramucirumab SWOT Analysis, 2013 87
Table 27: Product Profile custirsen (OGX-011) 88
Table 28: custirsen SWOT Analysis, 2013 92
Table 29: Product Profile ganetespib (STA-9090) 93
Table 30: ganetespib SWOT Analysis, 2013 98
Table 31: Product Profile nintedanib (BIBF-1120) 99
Table 32: nintedanib SWOT Analysis, 2013 102
Table 33: Product Profile Gilotrif (afatinib) 103
Table 34: Gilotrif SWOT Analysis, 2013 107
Table 35: Product Profile dacomitinib (PF-00299804) 108
Table 36: dacomitinib SWOT Analysis, 2013 112
Table 37: Product Profile LDK378 113
Table 38: LDK378 SWOT Analysis, 2013 117
Table 39: Product Profile Yervoy (ipilimumab) 118
Table 40: Yervoy SWOT Analysis, 2013 121
Table 41: Product Profile nivolumab (BMS936558) 122
Table 42: nivolumab SWOT Analysis, 2013 127
Table 43: Product Profile GSK1572932A (MAGE-A3 immunotherapy) 128
Table 44: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 131
Table 45: Product Profile Halaven (eribulin mesylate) 132
Table 46: Halaven SWOT Analysis, 2013 135
Table 47: Sales Forecasts ($m) for NSCLC in Spain, 2012-2022 137
Table 48: Key Events Impacting Sales for NSCLC in Spain, 2012-2022 139
Table 49: NSCLC Market in Spain Drivers and Barriers, 20122022 140
Table 50: Five Year Prevalence 165
Table 51: Key Launch Dates 166
Table 52: Key Patent Expiries 167
Table 53: Physicians Surveyed by Country 183

List of Chart


Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 20122022 71
Figure 2: Sales for NSCLC in Spain by Drug, 20122022 138

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *